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Introduction
The oceans cover about 70% of the planet’s surface with 
a high biodiversity. Yet, very few marine species have 
been explored or used for pharmaceutical purposes. The 
bioactive metabolites of marine origin have attracted 
the attention of medical practitioners and scientists 
for the past few decades because several of these 
chemicals exhibit pronounced pharmacological activities. 
Seaweeds are classified as Rhodophyta (red algae), 
Phaeophyta (brown algae) or Chlorophyta (green algae) 
depending on their nutrient, pigments, and chemical 
composition and formed part of the traditional diet of 
coastal communities particularly in Japan, China and 
Korea. The discovery of metabolites with biological activity 
from seaweeds has increased substantially in the last 
three decades. These substances exhibit an appreciable 
number of distinct biological activities, such as anti-
tumoral, anti-viral, anti-fungal, insecticidal, cytotoxic, 
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phytotoxic, and anti-proliferative actions. Most of the 
bioactive substances isolated from seaweeds are chemically 
classified as brominated, aromatics, nitrogen-heterocyclic, 
nitrosulphuric-heterocyclic, sterols, dibutanoids, proteins, 
peptides, sulphated polysaccharides, terpenes, acetogenins, 
alkaloids and polyphenolics. Seaweeds are also the only 
sources for industrially important phycocolloids like 
agar, carrageenan and alginate which have applications 
as stabilizer, viscosifier, gelling and emulsifying agents.
Why seaweeds are prolific 
producer of pharmacologically 
active metabolites
Seaweeds were reported to possess structurally diverse 
compounds of various bioactivities endowed with 
antihypertensive, anti-inflammatory, and anticarcinogenic 
activities. These species which grows in saline habitats 
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Fig.2. Seaweed harvest from Indian seas
Fig.1. Cultured seaweed harvest at Mandapam, Tamil Nadu
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evolved a number of specialized biochemical mechanisms 
to withstand salt-triggered oxidative stress conditions, 
which is governed by multiple biochemical mechanisms 
facilitating cell homeostasis and ability for retention of 
water. However, the absence of oxidative damage in the 
structural components, deterrence of predation, and the 
ability to reproduce successfully suggest that their cells 
are the storehouse of bioactive metabolites with potential 
pharmacological properties. Therefore, these marine 
floras are considered as valuable sources of bioactive 
compounds with potential pharmacological significance.
Nutraceuticals from seaweeds
The rich diversity of seaweeds represents an untapped 
reservoir of bioactive compounds with valuable 
pharmaceutical and biomedical use. The pioneering research 
work at ICAR-Central Marine Fisheries Research Institute 
(CMFRI) involved chemical profiling of major species of 
seaweeds for lead pharmacophores coupled with evaluation 
of target biological activities against different disease 
models, for example, 3-hydroxy-3-methylglutaryl coenzyme 
A reductase, type-2 diabetes modulators (dipeptidyl 
peptidase-4, protein tyrosine phosphatase 1B), angiotensin 
converting enzyme, inflammatory cyclooxygenase-2 and 
5-lipoxygenase. Optimized physical/chromatographic 
procedures were developed to isolate and purify the 
molecules with target bioactivities.
A database of seaweeds with high-value bioactive molecules 
responsible to combat various life-threatening and lifestyle 
diseases could be developed. This research could also 
develop protocols to prepare nutraceutical products 
enriched with lead pharmacophores with different 
properties against various drug targets for use against 
hypothyroidism, dyslipidemia, hypertension, type-2 diabetes, 
and inflammatory disorders (Fig.3). The natural anti-
inflammatory supplements enriched with lead molecules as 
nutraceutical CadalminTM Green Algal extract (CadalminTM 
GAe) from seaweeds as effective green alternative to 
the synthetic drugs available in the market to combat 
rheumatic arthritic pains was subsequently out-licensed to 
the biopharmaceutical company for commercial production 
and marketing in India and abroad. The research efforts 
to isolate the lead molecules with action against type-
2 diabetes led to the development of a nutraceutical 
product CadalminTM Antidiabetic extract (CadalminTM 
ADe). CadalminTM Antihypercholesterolemic extract 
(CadalminTM ACe) and CadalminTM Antihypothyroidism 
extract (CadalminTM ATe) developed to combat dyslipidemia 
and hypothyroid disorders, respectively, were also out-
licensed to a pharmaceutical company.
What are nutraceuticals 
and how they are different 
from drugs?
The term “nutraceutical” was coined by Dr. Stephen 
DeFelice, founder and chairman of the Foundation 
for Innovation in Medicine who defined it as “any 
substance that is a food or a part of a food and provides 
medical or health benefits, including the prevention and 
treatment of disease”. Nutraceutical has been defined as 
“concentrated, isolated, or purified” pharmacologically 
bioactive molecules. Nutraceuticals are clearly not drugs, 
and unlike synthetic drugs, the potential pharmacologically 
active substances are derived from natural sources, and 
are concentrated by using green extraction/purification 
techniques. The purification process eliminates the 
unnecessary components in the product, and increases 
the quantities of the intended pharmacophore(s), which 
are specifically active against a particular disease. This 
apparently leads to greater pharmacological activities of 
the nutraceutical products, while maintaining the mean 
lethal dose (LD50) greater than the threshold limits indicate 
the safety of the products. The LD50 of the nutraceutical 
products developed by ICAR-CMFRI were found to be 
greater than 4000 mg/kg body weight of the mammalian 
subjects tested that indicated the safety of the products. 
Since early 2000s, the world has viewed the extensive 
growth of the billion dollar nutraceutical industry and 
nutraceuticals are the preferred product portfolio of the 
leading pharmaceutical companies in India and abroad. 
The greatest challenge remains to formulate the regulatory 
guidelines to enable the physicians to prescribe this 
group of specialized medicines, and this will encourage 
research and development of this group of products.
Nutraceutical products 
developed by ICAR-CMFRI
The nutraceutical products CadalminTM Green Algal extract 
(CadalminTM GAe) and Antidiabetic extract (CadalminTM 
ADe) as green alternatives to synthetic drugs to combat 
rheumatic arthritic pains and type-2 diabetes respectively, 
were developed from seaweeds by ICAR-CMFRI. CadalminTM 
Antihypercholesterolemic extract (CadalminTM ACe) and 
CadalminTM Antihypothyroidism extract (CadalminTM ATe) 
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developed to combat dyslipidemia and hypothyroid 
disorder, respectively were also commercialised. Semi-
synthetic C-4/C-6 methylene-polycarboxylate cross-linked 
hybrid drug delivery system and a topical antibacterial 
formulation developed from seaweeds were found to 
be comparable with commercially available products. 
The lead molecules from seaweeds, with action against 
angiotensin converting enzyme-I, were isolated and added 
to a nutraceutical product CadalminTM Antihypertensive 
extract (CadalminTM AHe). Seaweed-derived natural 
template inspired synthetic derivatives as potential 
pharmacophores with potential antibacterial activities 
against methicillin-resistant Staphylococcus aureus and 
anti-angiotensin-I inhibitory activities were also designed 
and developed. Several cosmeceutical products from 
seaweeds are also in pipeline or being commercialized.
CadalminTM ADe: The bioactive ingredients in CadalminTM 
ADe competitively inhibit dipeptidyl peptidase-4 and tyrosine 
phosphatase 1B thereby hindering the occurrence of type-2 
diabetes. Type-2 diabetes and obesity are characterized by 
resistance to hormones insulin, possibly due to attenuated 
or diminished signaling from the receptors. A large body 
of data have identified protein tyrosine phosphatase 1B 
(PTP1B) as a major negative regulator of insulin signaling. 
Pharmacological agents capable of inhibiting the negative 
regulator(s) of the signaling pathways like PTP 1B are 
expected to potentiate the action of insulin and therefore be 
beneficial for the treatment of type 2 diabetes. Antidiabetic 
extract inhibits PTP1B, thereby hindering the occurrence of 
type-2 diabetes. Another mode of action of Antidiabetic 
extract is inhibition of dipeptidyl peptidase-4 (DPP-4), which 
is an antigenic enzyme expressed on the surface of most 
cell types and is associated with immune regulation and 
signal transduction. DPP-4 inactivates the incertins GLP-
1 and GIP by removing amino acids from these peptide 
hormones. GLP-1 and GIP are essentially required for insulin 
secretion from the β-cells of pancreas. In vitro antidiabetic 
experiments showed that the active principles effectively 
inhibited DPP-IV, tyrosine phosphatase, and β-glucosidase. 
The results demonstrated the potential of the formulation 
to effectively inhibit the mediators, which are responsible 
to induce type-2 diabetes through various metabolic 
pathways. The product developed from seaweed was 
compared with that of standard drugs after administering 
the animals with streptozotocin (a diabetes inducer). The 
diabetic control had glucose level recorded at greater than 
380 mg/dL, whereas the blood glucose levels maintained 
at about 74 mg/dL (at 65 mg/kg body weight), when the 
animals were administered with the active ingredients. 
The HbA1c levels maintained at about 4.6% (the normal 
range being 4.3-6.3%) after administering the animals 
with the nutraceutical product. The active principles 
of CadalminTM Antidiabetic extract from seaweeds thus 
effectively inhibit various mediators, which are responsible 
for inducing type-2 diabetes through various metabolic 
pathways. The bioactive ingredients in the nutraceutical 
product interfere with the release of simple sugars from 
the gut, which in turn reduces postprandial (after eating) 
hyperglycemia (high blood sugar levels). It has no side 
effects (LD50 > 5000 mg/kg body weight) as proved from 
the preclinical and acute/long term chronic toxicity studies 
on experimental subjects. The active ingredients in the 
product packed in plant-based capsules to meet the dietary 
needs of vegetarians has a promising consumer appeal, 
and market potential especially for the large vegetarian 
population in India and abroad.
CadalminTM GAe: The product is effective for combating 
arthritic pain and inflammatory diseases in human beings. 
The active principles in CadalminTM GAe competitively 
inhibit pro-inflammatory mediators, resulting in 
Fig. 3. Nutraceuticals developed by ICAR-Central Marine Fisheries Research Institute for use against rheumatoid arthritis, type-2 
diabetes,obesity/dyslipidemia,hypothyroidism and hypertension (Left to right)
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decreased production of inflammatory prostaglandins 
and leukotrienes, and its activity was found to be superior 
to some of the synthetic non steroidal anti-inflammatory 
drugs available in the market. A lower cycloxygenase-1/5-
lipoxygenase and cycloxygenase1/2 (<1.0), simultaneous 
inhibition of cycloxygenase-2 and 5-lipoxygenase enzymes 
and significant in vivo activity indicate higher selectivity 
and lower side-effect profiles of CadalminTM GAe as 
compared to the synthetic non-steroidal anti-inflammatory 
drugs. Time dependent in vivo animal model studies on 
experimental subjects revealed the superior inhibition 
of inflammatory response to the tune of 73-76% by 
Cadalmin™ GAe. Long term animal model experiments 
proved the efficiency and safety of this nutraceutical. 
CadalminTM GAe suppresses the edema produced by 
histamine, and exhibits its anti-inflammatory action by 
means of either inhibiting the synthesis, release or action 
of anti-inflammatory mediators. The mean lethal dose 
(LD50) of CadalminTM GAe was found to be greater than 
4000 mg/kg body weight of the mammalian subjects 
that indicate the safety of the product. As part of the 
preclinical assay of the product, feeding of CadalminTM 
GAe even at a dose upto 2500 mg/kg body weight 
did not induce significant change in body weights, 
hematological indices, histopathological, and serum 
biochemical parameters between the control and treated 
groups. This product has been commercialized with a 
biopharmaceutical company and ICAR-CMFRI is in search 
of more commercial partners for wider dissemination of 
the product in the marketplace.
CadalminTM ACe: Bioactive pharmacophore leads 
from seaweeds were used to develop the nutraceutical 
product, and were found to inhibit hydroxymethyl glutaryl 
coenzyme A reductase, various target receptors and other 
rate limiting enzymes, which are responsible to cause 
obesity and dyslipidemia. The total cholesterol (~ 90 mg/
dl), triglyceride (TG 88.14 mg/dl), high density cholesterol 
(HDL 39.18 mg/dl), low density cholesterol (LDL 28.09 mg/
dl) and very low density cholesterol (VLDL 22.36 mg/dl) 
were found to be within the acceptable limits after oral 
administration of the product in the mammalian subjects, 
with respect to positive control (total cholesterol 185.5 
mg/dl, TG 193.28 mg/dl, HDL 33.65 mg/dl, LDL 110.9 
mg/dl and VLDL 38.86 mg/dl). In-vivo evaluation of the 
product prevents high fat-induced (HFD) hyperlipidemia, 
characterized by significantly lower level of serum LDL 
(28.09 mg/dL), lipid peroxidation status (1.93 nmoles/mg 
protein) and, substantially lower atherogenic index (0.11 
mg/g tissue), constitutes a promising anti-lipidemic efficacy 
of the formulation. hydroxymethyl glutaryl reductase 
enzyme inhibitory activity of the formulation was found 
to be greater than 90% at a concentration of 5 mg/mL. 
This product showed potential to inhibit hydroxymethyl 
glutaryl reductase (IC50 0.15 mg/mL), an established statin 
target, and reduce obesity and hypercholesterolemic 
disorders as determined by the in vivo mammalian model. 
Other liver and lipid parameters, which clinically signify 
dyslipidemia and obesity, were also found to be within 
the clinically acceptable limits. Time dependent shelf life 
studies conducted to identify the oxidative changes for 
the product in an accelerated shelf-life study revealed 
that the content of the bioactive pharmacophores of the 
product on shelf for a period equivalent to 24 months 
exists. The product was out-licensed in 2017.
CadalminTM AHe: The active principles of CadalminTM AHe 
from seaweeds effectively inhibit various mediators, which 
cause hypertension through various metabolic pathways. 
It blocks angiotensin converting enzyme that converts 
angiotensin I to angiotensin II. The bioactive ingredients in 
the nutraceutical product effectively modulate the serum 
level of oxidative stress marker nitric oxide, lipid peroxidase 
and the potent vasoconstrictor angiotensin-II which increases 
blood pressure, and promotes inflammation and remodeling 
of the cardiovascular system, which leads to thrombosis or 
ventricular hypertrophy. Animal model anti-hypertension 
experiments showed that the active principles effectively 
decreased the angiotensin-II levels in the cadmium chloride 
(CdCl2) induced hypertension in rats. Serum nitric oxide, lipid 
peroxidase and angiotensin-II levels were also significantly 
decreased in hypertension affected group treated by 
CadalminTM AHe. In CdCl2 plus CadalminTM AHe group serum 
NO level has been significantly regulated upto 8.5 µg/dL 
at 100 mg/kg body weight and 9.00 µg/dL at 200 mg/kg 
body weight compared to the diseased group (13.06 µg/dL 
at 100 and 200 mg/kg body weight) and positive control 
group (9.17 µg/dL at 100 and 200 mg/kg body weight). 
The serum angiotensin-II level in CdCl2 + CadalminTM AHe 
group were comparatively lesser 0.205 pg/mL at 200 mg/
kg body weight than the diseased group (0.432 pg/mL at 
200 mg/kg body weight) and positive control (0.211 pg/
mL at 200 mg/kg body weight). Preclinical trials showed 
no toxicity related significant changes in renal or hepatic 
function, hematological indices and serum biochemical 
parameters in the experimental subjects. The results also 
demonstrated a lack of test substance-related general organ 
or systemic toxicity and hypertensive disorders following oral 
administration at a dose as high as 2000 mg/kg/d. No side 
effects (LD50 > 4000 mg/kg BW) as proved from the acute/
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long term chronic toxicity studies on experimental subjects 
were recorded. This product is available in encapsulated 
form and is intended to be used as oral application. Large 
scale extraction of the active principles from the raw material 
was optimized in a factory unit.
CadalminTM ATe: This nutraceutical with anti-hypo 
thyroidism principles extracted from seaweed, with an 
ecofriendly “green” technology has been commercialized 
by a leading Indian MNC in wellness during the year 2018. 
The bioactive leads concentrated in CadalminTM ATe were 
found to stimulate thyroid releasing hormone and increase 
the activity of selenodeiodinase to produce metabolically 
active thyroid hormones tetraiodothyronine (T4) and 3, 5, 
3′-triiodothyronine (T3). The current mode of treatment 
for hypothyroidism is levothyroxine-replacement therapy. 
However, there are certain limitations associated with this 
as it requires lifelong treatment, and is associated with 
poor compliance in some patients. Hence effective and 
alternative therapeutic strategies to treat hypothyroidism 
have been sought. The TSH in thyroid gland is responsible 
for the synthesis, storage and release of metabolic hormones 
thyroxine (T4) passive hormone containing four iodine and 
triiodothyroxine (T3) active hormone. The predominant 
hormone produced by the thyroid gland is T4, with 
approximately 70-90 mcg of T4 and 15-30 mcg of T3 
produced daily. The production of the T3 hormone by the 
thyroid gland is insufficient to meet the daily requirements 
of the organs in the body. Therefore, approximately 80% of 
the body’s required T3 comes from peripheral conversion 
of T4 to T3. Although both T4 and T3 are active, T3 is more 
active as thyroid receptors within the cell nucleus have a 
10-fold greater affinity for T3. In vivo anti-thypothyroidism 
experiments showed that the active principles effectively 
increased thyroid stimulating hormone to produce thyroid 
hormones (T3 and T4) into various experimental groups with 
healthy control and hypothyroidism induced by administering 
methimazole (MTZ) @100-150 mg/kg body weight (@
one-time dose for 15 days). Serum T3, T4 and TSH levels 
were significantly decreased in hypothyroid group. MTZ is a 
reversible goitrogen and induces hypothyroidism by inhibiting 
crucial enzyme deiodinase required for thyroid hormone 
synthesis. Inhibition of deiodinase impairs the iodination of 
tyrosyl residues and coupling of iodotyrosyl residues to form 
iodothyronine. Hypothyroid rats treated with CadalminTM 
ATe exhibited an improved thyroid profile. In MTZ+active 
ingredient groups with and without bioactive ingredients 
from seaweed, serum T3, T4 and TSH levels were significantly 
elevated respectively compared to diseased group. The 
results demonstrated the potential of CadalminTM ATe to 
effectively stimulate the production of thyroid hormones. 
CadalminTM ATe developed from seaweed was compared 
with that of standard drugs after administering the animals 
with methimazole (MTZ) (a hypothyroidism inducer). Serum 
triiodothyronine (T3) level for the active ingredient with 
CadalminTM ATe treated group (1.4 ng/dL at 150 mg/kg 
body weight) was greater than the active ingredient alone 
treated group (0.7 ng/dL at 150 mg/kg body weight) and 
positive control group (~1 ng/dL). Notably thyroxine (T4) 
level for the active ingredient with CadalminTM ATe treated 
group (9 µg/dL at 150 mg/kg body weight) was greater 
than the active ingredient alone treated group (5 µg/dL at 
150 mg/kg body weight) and positive control group (6 µg/
dL). One of the bioactive components combines with the 
tyrosine (aromatic amino acid) to synthesize thyroid hormones 
to create a more stable, steady supply of iodine for the 
thyroid. The deiodinase-activativing bioactive component 
in CadalminTM ATe was found to play significant role in the 
control of thyroid hormone metabolism and hence useful 
to treat hypothyroidism.
Conclusion
Seaweed derived bioactive components with potential 
health benefits are an emerging area of research. Seaweeds 
have a long tradition as a food source in Asian countries, 
being part of the Western diet only to a limited extent. 
In 2014, production of seaweeds through mariculture 
(44% of all aquaculture) was estimated at about 27 
million tons wet weight, registering annual growth 
rate of 8% and valued at 7 billion US$ (FAO 2016). The 
Regional Centre ICAR-CMFRI at Mandapam, Tamil Nadu 
ventured to develop indigenous cultivation technology 
for seaweeds since 1970s. Considering the present status 
of under-utilization of seaweeds, exploring bioactive 
compounds and development of any biologically useful 
products can bring dual benefits-one, as health products 
and secondly, commercial farming in coastal habitats, 
resulting in C-sequestration and C-budgeting in a scenario 
where global climate change poses a serious threat. 
Development of value-added products from these 
underutilized species will promote their farming in coastal 
habitats, which has not been seriously explored earlier 
due to the lack of knowledge about their commercial 
importance. Devoted research program to develop various 
health products from seaweeds will also pave the way 
to effectively harness the potential of this natural wealth 
of Indian coastal waters.
